DESTOCK +

DESTOCK + è un integratore alimentare dichiarato in Francia. Stato: dichiarato in Francia, commercializzazione possibile. 2 norme d’uso si applicano ai suoi ingredienti (limiti e avvertenze).

Marca

non indicata

Responsabile dell’immissione in commercio

LINEA B

Stato

Dichiarato in Francia, commercializzazione possibile: l’amministrazione non si è opposta alla dichiarazione (non è né un’autorizzazione né una valutazione della sicurezza)

Forma

Flacone

Dose giornaliera

20ml

Modalità d’uso

Traduzione non disponibile. Testo originale, lingua: francese.

Prendre 20ml à l'aide du gobelet doseur, purs ou dilués dans un verre d'eau, 1 fois par jour.

Compl’Alim, dichiarazioni di integratori alimentari · 2023-04-07T14:00:00+02:00

Sconsigliato (secondo il fabbricante)

Adolescenti (sotto i 18 anni), Donne che allattano, Bambini (sotto i 12 anni), Donne in gravidanza

Obiettivi dichiarati dal fabbricante (non sono indicazioni autorizzate)

Dimagrimento / Bruciagrassi

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

• Capsicum annuum L.
  Leggere l'avvertenza, quando si applica e gli studi citati

  Testo originale ufficiale in inglese.

  CAYENNE - CAPSICUM ANNUUM Oral

  Precauzioni e avvertenze

  Condizione di applicazione: All products.

  Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

  Fonti citate da Health Canada (1)

  • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

  Fonti citate da Health Canada (2)

  • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
  • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

  Fonti citate da Health Canada (1)

  • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

  Condizione di applicazione: Digestion; Peripheral circulation.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

  Monografia di Health Canada del 27 marzo 2026

  CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

  Precauzioni e avvertenze

  Condizione di applicazione: All products.

  For external use only (US FDA 2023).

  Fonti citate da Health Canada (1)

  • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

  1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

  When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

  Fonti citate da Health Canada (1)

  • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

  1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

  Fonti citate da Health Canada (1)

  • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

  1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

  Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

  Fonti citate da Health Canada (1)

  • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

  Reazioni avverse note

  Condizione di applicazione: All products.

  Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

  Fonti citate da Health Canada (5)

  • APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
  • Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
  • Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
  • McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Studio randomizzato
  • Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Revisione sistematica

  Monografia di Health Canada del 27 marzo 2026

• Sambucus nigra L.
  Leggere l'avvertenza, quando si applica e gli studi citati

  Testo originale ufficiale in inglese.

  ELDER – SAMBUCUS

  Via di somministrazione: Oral

  Precauzioni e avvertenze

  Condizione di applicazione: All products.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

  Condizione di applicazione: Diaphoretic; Symptoms of colds, flus; Sinusitis, hay-fever; Joint pain.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

  Reazioni avverse note

  Condizione di applicazione: All products.

  Stop use if hypersensitivity/allergy occur (Forster-Waldl et al. 2003).

  Fonti citate da Health Canada (1)

  • Förster-Waldl E, Marchetii M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Jäger S, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Type I allergy to elderberry (Sambucus nigra) is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins. Clinical and Experimental Allergy 2003;33(2):1703-1710. PubMed

  Condizione di applicazione: All products except those making a diuretic claim.

  When using this product diuretic effect may occur (Bradley 1992; Winston and Kuhn 2008; Barnes et al. 2007; Hoffman 2003).

  Fonti citate da Health Canada (2)

  • Barnes J, Anderson LA, Philipson JD. Herbal Medicines. 3rd edition. London (GB): The Pharmaceutical Press; 2007.
  • Winston D and Kuhn MA. Herbal Therapy & Supplements A Scientific and Traditional Approach. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

  2 studi citati nel testo non hanno un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

  Monografia di Health Canada del 19 dicembre 2025

• Caféine
  Leggere l'avvertenza, quando si applica e gli studi citati

  Testo originale ufficiale in inglese.

  CAFFEINE

  Via di somministrazione: Oral (Higdon and Frei 2006)

  Precauzioni e avvertenze

  Si applica ai prodotti: providing 100 mg to 400 mg caffeine, per day1.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

  Fonti citate da Health Canada (7)

  • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
  • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Studio randomizzato
  • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
  • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Articolo di revisione
  • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Studio clinico
  • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analisi
  • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analisi

  1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

  Si applica ai prodotti: providing more than 300 mg caffeine, per day.

  Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

  Fonti citate da Health Canada (1)

  • Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Articolo di revisione

  Si applica ai prodotti: providing 400 mg or more caffeine, per day.

  When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

  Fonti citate da Health Canada (8)

  • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
  • Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Caso clinico
  • Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Studio randomizzato
  • FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
  • Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Studio randomizzato
  • NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
  • Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Caso clinico
  • Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.

  Controindicazioni

  Si applica ai prodotti: providing more than 400 mg caffeine per day.

  Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

  Fonti citate da Health Canada (7)

  • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
  • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Studio randomizzato
  • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
  • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Articolo di revisione
  • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Studio clinico
  • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analisi
  • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analisi

  Reazioni avverse note

  Condizione di applicazione: All products.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

  Fonti citate da Health Canada (2)

  • Hinrichs R, Hunzelmann N, Ritzkowsky A, Zollner TM, Krieg T, Scharffetter-Kochanek K. Caffeine hypersensitivity. Allergy 2002;57(9):859-860. PubMed Caso clinico
  • Infante S, Baeza ML, Calvo M, De Barrio M, Rubio M, Herrero T. Anaphylaxis due to caffeine. Allergy 2003;58(7):681-682. PubMed Caso clinico

  Si applica ai prodotti: providing 200 mg or more caffeine, per day.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

  Fonti citate da Health Canada (1)

  • Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.

  Si applica ai prodotti: providing more than 400 mg caffeine, per day.

  Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

  Fonti citate da Health Canada (3)

  • IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
  • Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Articolo di revisione
  • Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Articolo di revisione

  Condizione di applicazione: All products except those making a diuretic claim1.

  When using this product diuretic effect may occur.

  1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

  Monografia di Health Canada del 19 dicembre 2025